10-Q: Recursion Pharmaceuticals Reports First Quarter 2024 Financial Results, Highlights Pipeline Progress and Platform Advancements

Recursion Pharmaceuticals' first quarter 2024 results show increased R&D spending as the company advances its pipeline and platform, while also reporting a net loss of $91.4 million.

Summary

• Recursion Pharmaceuticals reported a net loss of $91.4 million for the first quarter of 2024, compared to a net loss of $65.3 million for the same period in 2023.
• The company's operating revenue increased to $13.5 million, up from $12.1 million in the first quarter of 2023, primarily due to revenue recognized from the Roche partnership.
• Research and development expenses rose significantly to $67.6 million, a 45% increase from $46.7 million in the prior year, driven by platform expansion, preclinical pipeline advancement, and clinical trial progress.
• General and administrative expenses also increased to $31.4 million, up from $22.9 million in the first quarter of 2023, due to higher salaries, software costs, and depreciation.
• The company's cash and cash equivalents totaled $296.3 million as of March 31, 2024, down from $391.6 million at the end of 2023.
• Recursion believes its current cash and cash equivalents will be sufficient to fund operations for at least the next 12 months.
• The company has an accumulated deficit of $1.1 billion as of March 31, 2024.
• The company is progressing multiple clinical trials, including REC-994 for Cerebral Cavernous Malformation, REC-2282 for Neurofibromatosis Type 2, and REC-4881 for Familial Adenomatous Polyposis and AXIN1 or APC Mutant Cancers.
• Recursion is also advancing its platform, including the BioHive-2 supercomputer and whole-genome transcriptomics map.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in pipeline development and platform expansion, the significant increase in net loss and operating expenses, along with the need for future capital raises, temper the overall sentiment. The material weakness in internal controls is also a concern.

Positives

• Operating revenue saw an 11% increase year-over-year, indicating growth in strategic partnerships.
• The company is making significant progress in its clinical pipeline with multiple trials underway.
• The expansion of the BioHive supercomputer and transcriptomics capabilities demonstrates a commitment to technological advancement.
• The company has secured access to large datasets through collaborations with Helix and Tempus, enhancing its AI/ML capabilities.
• The company believes its current cash and cash equivalents will be sufficient to fund operations for at least the next 12 months.

Negatives

• The company reported a net loss of $91.4 million for the quarter, a significant increase from the $65.3 million loss in the same period last year.
• Research and development expenses increased substantially, indicating high operational costs.
• General and administrative expenses also increased, contributing to the overall loss.
• The company's cash reserves decreased from $391.6 million to $296.3 million during the quarter.
• The company has an accumulated deficit of $1.1 billion.

Risks

• The company is subject to risks and uncertainties similar to other biotechnology companies, including the uncertainty of clinical trial outcomes and the need for additional funding.
• The company relies on third parties for research and clinical trials, which could lead to delays or failures.
• The company may be impacted by U.S. legislation, sanctions, trade restrictions, or other U.S. and foreign regulatory requirements, prohibitions or restrictions, limiting or preventing the ability to enter into arrangements with foreign third parties.
• The company has identified a material weakness in internal controls related to revenue and unearned revenue processes.
• The company is involved in legal proceedings related to a lease agreement, which could have a material impact on its financial position.

Future Outlook

The company expects to continue to incur substantial operating losses and will require additional capital to advance its drug candidates. Recursion believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditures for at least the next 12 months. The company anticipates sharing Phase 2 data for REC-994 in Q3 2024 and Phase 2 safety and preliminary efficacy data for REC-2282 in Q4 2024.

Management Comments

• The company is focused on scaling and leveraging the Recursion OS to generate, aggregate, and integrate data.
• The company believes its unbiased, data-driven approach to understanding biology will bring more, new, and better medicines at higher scale and lower cost to patients.
• The company is advancing efforts to discover potential new therapeutics with strategic partners.
• The company is working with NVIDIA to design and build BioHive-2, its next-generation supercomputer.

Industry Context

Recursion's focus on integrating AI and machine learning into drug discovery aligns with the broader industry trend of leveraging technology to accelerate and improve the drug development process. The company's partnerships with major pharmaceutical and technology companies highlight the growing importance of collaboration in this space. The company's focus on precision oncology and genetically driven rare diseases is also consistent with the industry's move towards more targeted therapies.

Comparison to Industry Standards

• Recursion's R&D spending as a percentage of revenue is high, which is typical for a clinical-stage biotech company focused on platform development and multiple clinical programs. This is comparable to companies like Relay Therapeutics and AbCellera, which also invest heavily in technology and early-stage drug development.
• The company's net loss is significant, but not unusual for a company at this stage of development. Many biotech companies experience substantial losses while advancing their pipelines. Companies like CRISPR Therapeutics and Editas Medicine also report significant losses as they invest in R&D.
• The company's cash position is relatively strong, providing a runway for at least the next 12 months. This is comparable to other well-funded biotech companies, but the need for future capital raises is a common theme in the industry.
• The company's focus on AI and machine learning is a differentiator, but many companies are now incorporating these technologies. Recursion's large proprietary dataset and supercomputing capabilities are a competitive advantage, similar to companies like Schrodinger that have built their own proprietary platforms.
• The company's partnerships with Roche and Bayer are significant, indicating validation of its approach by established pharmaceutical companies. This is similar to other biotech companies that collaborate with larger players to share risk and resources.

Management Changes

Legal Proceedings

• The company is involved in a legal dispute with Industry Office SLC, LLC regarding a lease agreement, alleging breach of contract and fraudulent misrepresentation.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the need for future capital raises, which could dilute their ownership.
• Employees may be impacted by the company's financial performance and any potential restructuring or cost-cutting measures.
• Customers and partners may be interested in the progress of the company's clinical trials and platform development.
• Creditors may be monitoring the company's financial health and ability to repay its debts.

Next Steps

• The company expects to share Phase 2 data for REC-994 in Q3 2024.
• The company expects to share Phase 2 safety and preliminary efficacy data for REC-2282 in Q4 2024.
• The company expects to share Phase 2 safety and preliminary efficacy data for REC-4881 in H1 2025.
• The company expects to initiate a randomized Phase 2 study in patients at high risk for C. difficile infection recurrence in 2024.
• The company expects to submit an IND for RBM39 in H2 2024.
• The company expects to complete the whole-genome knockout transcriptomics map in the coming quarters.

Key Dates

Keywords

drug discovery, clinical trials, AI, machine learning, biotechnology, genomics, transcriptomics, supercomputer, precision oncology, rare diseases, pharmaceuticals, data science, partnerships, R&D, BioHive